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I
n the spring of 2007, just weeks before my college gradu-
ation, my parents called to tell me that my grandmother 
was sick. I was worried to hear that she was in the hospital, 
but like the rest of my family, I had little doubt that she’d be 
better in no time. At a spry 82 years, my grandmother was 
the picture of health. She was a nonsmoker, a nondrinker, 
and had had no medical problems except for mild asthma. 
A world traveler, avid gardener, and savvy businesswom-
an, she has been known to do her grocery shopping, at-
tend a bank board meeting, talk her way out of a speeding 
ticket, and rearrange the living room furniture all in time to 
prepare dinner for 12 and cut fresh roses for the table. As 
a loving wife, mother of 5, and grandmother of 10, she is 
the family matriarch and holds us together in a way I never 
fully appreciated until that familiar structure was suddenly 
threatened.
My grandmother’s illness began with acute onset of ab-
dominal cramps and watery, nonbloody diarrhea followed 
by nausea and vomiting. She had no fever. The diarrhea 
continued intermittently through the first day and night of 
her illness, and by the second day, when the diarrhea be-
came grossly bloody, her internist had her admitted to a 
community hospital.
At the time of admission, she was normotensive and 
still afebrile. Physical examination findings were unremark-
able except for mild bilateral lower abdominal tenderness. 
The leukocyte count was mildly elevated at 13,500 cells/
μL, hemoglobin was within normal limits at 15.0 g/dL, and 
the platelet count was 263,000 cells/μL. Electrolytes were 
within normal limits, blood urea nitrogen was mildly ele-
vated at 19 mg/dL, and creatinine was within normal limits 
at 0.7 mg/dL. Urinalysis findings were also within normal 
limits. A radiograph of her abdomen showed no signs of 
a  perforated  organ.  Gastroenterologists  were  consulted. 
Their assessment suggested infectious diarrhea as the most 
likely diagnosis, followed by ischemic colitis and divertic-
ular disease. To check for enteric infections, they ordered 
stool culture, stool leukocyte count, and a stool Clostridium 
difficile toxin test. Supportive treatment of intravenous hy-
dration and antiemetics was initiated.
On my grandmother’s third day of illness, the bloody 
diarrhea worsened and the leukocyte count increased to 
18,100 cells/μL. A stool sample contained no C. difficile 
toxin but did contain leukocytes. A contrast computed to-
mography (CT) scan of the abdomen showed pancolitis 
with 2-cm wall edema and narrowing of the colon lumen. 
The CT findings of colitis distributed throughout multiple 
vessels, sparing of the terminal ileum, and good contrast 
flow in the major mesenteric vessels made a diagnosis of 
ischemic colitis much less likely; therefore, bacterial pan-
colitis became the leading diagnosis. Because of increas-
ingly severe bloody diarrhea and leukocytosis, intravenous 
ciprofloxacin and metronidazole were started empirically 
while stool culture results were pending.
Over the next 2 days, the bloody diarrhea abated, but 
abdominal distention and a mild tremor developed. An ab-
dominal radiograph showed air distending the stomach and 
small bowel. The leukocyte count rose to 30,500 cells/μL, 
and the platelet count dropped to 105,000 cells/μL. Low 
urine output, blood urea nitrogen level of 57 mg/dL, and 
creatinine level of 1.9 mg/dL suggested acute kidney in-
jury, for which increased intravenous fluids and a diuretic 
were ordered.
None of these developments were overly alarming; 
nevertheless,  my  grandmother  looked  sicker,  and  my 
family’s concern deepened. My father (M.L.C.), an or-
thopedic surgeon, was growing increasingly uneasy, but 
because hemorrhagic colitis was not his area of expertise, 
he was content to defer to his colleagues’ judgment. How-
ever, as a physician and son, he felt compelled to fully un-
derstand his mother’s illness. He began by searching the 
literature on infectious hemorrhagic colitis and learned 
that the major bacterial causes are Shigella, Salmonella, 
Yersinia, Vibrio, Escherichia coli, Campylobacter, and 
Clostridium spp. (1). He then visited the hospital’s bacte-
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riology laboratory, where a technician explained the lab’s 
stool culture protocol.
My father learned that stool culture on commonly used 
culture media is quite effective for identification of Salmo-
nella spp. and other bacteria not normally found in human 
bowel. However, because E. coli is part of normal bowel 
flora, a separate strategy is needed to distinguish diarrhe-
agenic E. coli serotypes from their nonpathogenic brethren. 
To do this, most laboratories use a selective medium called 
sorbitol-MacConkey agar (SMAC) to identify the patho-
genic serotype E. coli O157:H7. Whereas most other E. 
coli serotypes ferment sorbitol and grow as pink colonies, 
this serotype does not ferment sorbitol and grows as color-
less colonies. When my father asked how often stool cul-
ture results from patients with actual bacterial colitis were 
negative, the technician assured him, “almost never.” Thus, 
when my grandmother’s stool culture came back negative, 
my father did not question it.
On my grandmother’s fifth day of illness, colonoscopy 
showed  severe  nodular  and  granular  inflammation  from 
rectum to cecum. The gastroenterologist excluded ischemic 
colitis but, given the negative culture and the colonoscopic 
appearance, had to consider the possibility of inflammatory 
bowel disease. Although new onset of this disease was un-
likely in an 82-year-old patient, this possibility was cov-
ered by prescribing a full dose of steroids; ciprofloxacin 
was continued. In the meantime, my father continued his 
literature search, which reinforced his feeling that inflam-
matory bowel disease was unlikely.
When  my  father  refocused  his  search  on  infectious 
causes of hemorrhagic colitis, E. coli emerged as the most 
frequently described culprit and seemed consistent with my 
grandmother’s case. He further learned that the serotypes 
of E. coli that cause diarrheal illness in humans do so by 
producing Shiga toxin and are thus referred to as Shiga tox-
in–producing E. coli (STEC); that the O157:H7 serotype is 
the most frequently identified type of STEC in the United 
States; and that it is the most likely serotype to cause hemo-
lytic–uremic syndrome (HUS), a life-threatening condition 
characterized  by  hemolytic  anemia,  low  platelet  count, 
and renal failure. He also came across several articles that 
gave him pause. One recent article stated that 20%–50% 
of all STEC infections in the United States are caused by 
non-O157 STEC serotypes, some of which can cause HUS 
(2). A second article explained that non-O157 STEC is not 
detected by SMAC because, like nonpathogenic E. coli, it 
ferments sorbitol. Instead, both O157 and non-O157 STEC 
could be detected by enzyme immunoassay for Shiga toxin 
(3). My grandmother’s negative stool culture now seemed 
less conclusive.
The next morning, the sixth day of illness, my grand-
mother was transferred to an intensive care unit because of 
worsening renal failure. Her mental status had declined and 
her tremor had worsened. My father suspected HUS and 
conveyed his concern to her internist, who agreed that HUS 
was a possibility. My father then returned to the laboratory 
and inquired about the Shiga toxin assay he’d read about. 
The technician told him that they had recently opted not to 
buy the toxin assay because of its expense and their satis-
faction with SMAC; however, the toxin assay was avail-
able at their reference laboratory. Unfortunately, the origi-
nal stool sample had been discarded. A new specimen was 
collected, sent, and had negative results for Shiga toxin, but 
it also grew no gram-negative bacteria on culture. Three 
days of antimicrobial drugs had effectively sterilized the 
colon, rendering a false-negative result more likely. That 
afternoon, the hemoglobin level decreased to 12.0 g/dL, 
platelet count fell to 71,000 cells/μL, and lactate dehydro-
genase level was markedly elevated, all of which could be 
consistent with developing HUS. Although no schistocytes 
were evident on peripheral blood smear, the internist was 
concerned  and  consulted  a  nephrologist  at  a  nearby  re-
gional hospital. Upon hearing of suspected HUS, he rec-
ommended immediately transferring my grandmother for 
plasmapheresis and possible dialysis.
The next 12 hours were a blur of confusion and frus-
tration for my family. When care of a patient is transferred 
from one medical team to another, treatment plans often 
change abruptly, sometimes because of differences in clini-
cal judgment and other times because of imperfect com-
munication between the teams. Whatever the reason, my 
grandmother left her local hospital with a plan for plas-
mapheresis and supportive care for HUS, and 1 hour later, 
after evaluation at the regional hospital, received a diag-
nosis of acute abdomen and sepsis. A general surgeon was 
consulted and recommended emergency total colectomy. 
Without it, he said, she would be dead within the hour. My 
family was shocked and distressed by this drastic change 
of plans. My father was particularly hesitant. In his reading 
about the recommended therapy for STEC and HUS, he 
had not come across any mention of the need for surgical 
intervention. Nevertheless, the general surgeon was ada-
mant in his recommendation, and considering the surgical 
adage “You can never go wrong by looking,” my father 
advised my grandfather to consent to the operation.
Four hours later, the surgeon returned and explained 
to the family that the operation had gone well. He had re-
moved all but the distal 12 inches of the colon, which was 
not as severely affected. He expected that my grandmother 
would need mechanical ventilation, at least overnight and 
possibly for 1–2 days. The colon had been reddened and 
inflamed, but he had found no dead bowel and no perfora-
tions. He had noted 1-cm wall edema. Recalling the 2-cm 
wall edema on the CT image from 3 days ago, my father 
concluded that the colon had been recovering and regretted 
his decision to allow the operation.
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family learned everything they could about STEC. After 
learning that it is most frequently transmitted through un-
dercooked beef or contaminated produce, they analyzed 
their food history. This prompted the discovery of “The 
Meatloaf,” now infamous in our family lore. Three days 
before becoming ill, my grandmother had cooked a meat-
loaf for dinner, which a family member recalled being a 
bit pink in the middle. Over the next 4 days, all 3 other 
family members who had eaten the meatloaf experienced 
mild nonbloody diarrhea but recovered fully. My 4-year-
old cousin, who had refused to eat any meatloaf, showed 
no signs of illness. For once we were grateful for his picky 
eating. The ground beef in the meatloaf had come from 2 
calves from the family farm; the calves had been processed 
at a local slaughterhouse. Another piece of the puzzle had 
fallen into place.
Meanwhile, my grandmother continued to need me-
chanical ventilation and became comatose and anuric. She 
was evaluated by physicians from the departments of gen-
eral surgery, infectious disease, nephrology, hematology, 
pulmonology, and pathology. Despite my father’s sugges-
tions regarding STEC and HUS, their various assessments 
of her condition culminated in a diagnosis of ischemic coli-
tis with sepsis resulting in acute renal failure, disseminated 
intravascular coagulation (DIC), and hypotensive brain in-
jury, from which she was not likely to recover.
Each of these diagnoses was far more common than 
STEC/HUS, but several things simply didn’t fit. First, the 
operative findings were inconsistent with ischemic colitis. 
Second, my grandmother lacked the fever and hypoten-
sion characteristic of sepsis. Her blood pressure had never 
dropped to an extent that would be expected to cause severe 
end-organ damage. Third, the leukocyte count remained 
markedly elevated despite removal of the suspected source 
of infection, a battery of potent antimicrobial drugs, and 
negative blood and urine cultures. The elevated leukocyte 
count did not fit with sepsis but might have represented 
acute inflammation associated with HUS (4). Finally, al-
though hemoglobin level and platelet count remained low, 
other coagulation study results were all within normal lim-
its, more consistent with HUS than DIC.
My family remained convinced of the STEC/HUS di-
agnosis. On postoperative day 6, my father requested that 
antimicrobial drugs be stopped. If she really had sepsis, she 
was dying from it in spite of them. If not, they were only 
obscuring the true diagnosis. The next day my father called 
the foodborne diseases division of the Centers for Disease 
Control and Prevention (CDC). He described my grand-
mother’s case to the physician on call, who agreed, with-
out reservation, with the diagnosis of STEC infection. He 
explained that sepsis and DIC rarely occurred with STEC 
infection and that surgery was almost never required. An-
timicrobial drugs were not recommended and might even 
hasten progression to HUS. Although not of proven effec-
tiveness, plasmapheresis was commonly used for treatment 
of HUS. With this further support of the diagnosis, my fa-
ther again presented his case to my grandmother’s physi-
cians, and her nephrologist agreed to start a trial of daily 
plasmapheresis.
Over the next 4 days my grandmother remained co-
matose, but her urine output slowly began to increase. A 
nephrologist at a university medical center was consulted 
and recommended continuing plasmapheresis. That after-
noon, my grandmother opened her eyes. By the end of the 
day—the 16th day of illness—she was recognizing fam-
ily members, following simple commands, and mouthing 
words. She could turn her head to look at my grandfather, 
who was promising her everything in the world. As a com-
bat pilot in World War II, he’d seen his share of battles but 
none like this. After weeks of feeling lost, helpless, and un-
able to save his war-time bride, he now regained hope. My 
family’s relief was indescribable.
Histopathology  slides  of  my  grandmother’s  colon 
were sent to a university medical center for review, where 
pathologists  diagnosed  acute  hemorrhagic  necrotizing 
colitis consistent with STEC infection. Three days after 
waking from the coma, my grandmother was transferred 
to that medical center for the remainder of her recovery—
incidentally, the same university I was attending as an un-
dergraduate. On the morning of commencement, I was able 
to visit her wearing my cap and gown. After 11 days in the 
university hospital and 18 days in a rehabilitation facility, 
she was finally discharged to go home. Exceeding all ex-
pectations, her kidneys and neurologic system recovered 
fully, and 15 months later her colostomy bag was removed. 
She is now back to doing all her usual activities—serving 
as bank director, babysitting her 2 youngest grandchildren, 
flying to Hawaii for vacation, and cooking for a crowd. Just 
not meatloaf.
As illustrated by this case report, STEC infection may 
be difficult to recognize clinically, so appropriate labora-
tory testing is crucial for accurate and timely diagnosis. Up 
to 20%–50% of STEC infections in the United States, or 
≈37,000 cases per year, are caused by non-O157 E. coli 
serotypes (2,5), some of which have been associated with 
severe disease and HUS (6,7). Failure to test for these sero-
types leads to underdiagnosis and underreporting of STEC 
infection, to the detriment of patient care and public health 
surveillance,  respectively.  A  2006  report  strongly  urges 
clinical diagnostic laboratories to assay all stool specimens 
for Shiga toxin, to simultaneously culture the specimens 
on SMAC for organism isolation, and to forward positive 
specimens to a public health laboratory (8). Because data 
with regard to implementation of these recommendations 
are lacking, we surveyed diagnostic laboratories in Tennes-
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see about their protocols for STEC detection and identified 
factors influencing their choice of protocol.
From  July  through  October  2008,  we  contacted  all 
clinical laboratories licensed to perform microbiologic or 
bacteriologic testing in Tennessee and conducted telephone 
and email interviews with supervisors. This survey was ap-
proved by our university’s institutional review board.
From 130 laboratories, we received 117 responses, a 
high response rate of 90%. Of these 117 respondents, 57 
(49%) performed stool cultures in house. Of these 57 labo-
ratories, 46 (81%) included STEC in their routine testing 
for enteric pathogens, 8 (14%) tested for STEC only in 
bloody specimens or only with a physician’s order, and 3 
(5%) did not test for STEC at all. We further asked the 
54 laboratories that tested any or all specimens for STEC 
about their STEC detection protocol. We found that 38 
(70%) of 54 used SMAC alone; 4 (7%) of 54 used Shiga 
toxin assay alone; and 12 (22%) of 54 used both. Only 8 
(15%) of the 54 laboratories used both tests concurrently, 
and 6 (11%) did so for all specimens as recommended by 
CDC in 2006.
The second part of our survey aimed to ascertain which 
factors influenced adherence to the 2006 CDC recommen-
dations. In the 38 laboratories that used SMAC alone, 13 
(35%) supervisors stated that they were not familiar with 
the Shiga toxin assay, and 24 (63%) claimed some famil-
iarity. These 24 were asked to identify reasons for choos-
ing SMAC over Shiga toxin assay. Of the 24, a total of 20 
(83%) thought that SMAC alone provides adequate STEC 
detection, 18 (75%) said SMAC was a better fit for their 
laboratory’s workflow and staffing situation, 17 (71%) said 
that they used SMAC because of its lower cost, and 12 
(50%) said that they used SMAC because laboratory per-
sonnel were unfamiliar with the Shiga toxin assay.
Our  survey  suggests  that  Tennessee  laboratories  fall 
short of best practice recommendations for detection of non-
O157 STEC; only 11% had fully implemented the CDC-rec-
ommended protocols. The key factors associated with non-
adherence were lack of familiarity with Shiga toxin assays 
and limited knowledge of current recommendations.
Although  laboratories  operate  under  the  constraints 
of third-party reimbursement, local economics, and insti-
tutional policy, knowledge of best practice recommenda-
tions is essential for making an informed choice of proto-
col. As evidenced in my grandmother’s case, appropriate 
laboratory practices must be complemented by physicians’ 
high  index  of  suspicion  and  familiarity  with  diagnostic 
techniques.  Ultimately,  it  is  the  treating  physician’s  re-
sponsibility  to  ensure  that  all  necessary  diagnostic  tests 
are ordered, whether in house or at a reference laboratory. 
The 2006 recommendations were recently emphasized in a 
2009 MMWR Recommendations and Reports article (9). It 
is our hope that this recent publication will further contrib-
ute to the improved diagnosis of STEC infections, to the 
benefit of public health, patients, and grandmothers.
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